FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

CF 1.98(b)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. BOSKET NO. SECIAL NO. 1506-1032-1 10/619,906 **APPLICANT** Andreas DIECKMANN et al.

GBOOP

1614

FILING DATEOD July 16,

2003

			U.S. PAT	ENT DOCUMENTS			
EXAMPLE RADIO MINI		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
fl	AA	US 2002/ 0037538 A1 corres. to WO 0186002	03/02	Trepicchio et al.			
KC	AB	US 2003/ 0036070 Al corres. to WO0129269	02/03	Chakravarti			
KC	AC	5,506,242	04/96	MacPherson et al.	1 /		
V	AD	US 2003/ 0157110 A1	08/03	An et al.		\	

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
KC	Al	98/04287	02/98	WO	_	<i>f</i> :	
	AJ	20010580890	07/03	JP			
KC	AK	01/83461 A1 corres. to JP 20010580890	11/01	WO			English Abstract Of

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

4 in the properties of the section o							
KC	AT	Roscoe L. Warner et al., "Role of Metalloelastase (MMP-12) in a Model of Experimental Asthma," FASEB Journal, V. 16, 2002, p. A590, abstract.					
KC	AU	R. Dean Hautamaki et al., "Requirement for Macrophage Elastase for Cigarette Smoke-Induced Emphysema in Mice," Science, V. 277, 1997, pp. 2002-2004.					
KO	AV	Renu A. Heller et al., "Discovery and Analysis of Inflammatory Disease-Related Genes Using cDNA Microarrays," Proc. Natl. Acad. Sci. USA, V. 94, pp. 2150-2155.					
KC	AX	Maarit Vaalamo et al., "Distinct Expression Profiles of Stromelysin-2 (MMP-10), Collagenase-3 (MMP-13), Macrophage Metalloelastase (MMP-12), and Tissue Inhibitor of Metalloproteinases-3 (TIMP-3) in Intestinal Ulcerations, "American Journal of Pathology, V. 152, 1998, pp. 1005-1014.					
KC	AY	J. Michael Shipley et al., "Metalloelastase is Required for Macrophage-Mediated Proteolysis and Matrix Invasion in Mice," Proc. Natl. Acad. Sci USA, V. 93, pp. 3942-3946.					

EXAMINEB

DATE CONSIDERED

EXAMINES: Initial citation considered. Drawline through citation If not in conformance and not considered. include copy of this form with next communication to applicant.

			····				rage 2 Or 2	
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			AVTV. BOSKET NO. 1506-1032-1			\$60161 80. 10/619,906		
OMFORMATION DISCLOSURE STATEMENT BY APPLICABLY (Use several sheets if necessary)				APPLICANT Andreas DIECKMANN et al.				
				HIRE BATEON July 16, 2003				
			U.S. PAT	ENT DOCUMENTS				
FACASTER "INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE	
KC	ВА	6,352,976	03/02	Warshawsky et al.				
	BB					\swarrow		
	BC							
	BD	<u> </u>	<u> </u>			<u></u>		
FOREIGN	PATER	T OR PUBLISHED FOR	EIGH PATE	IT APPLICATION				
		DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO	
_ V (`	BL	01/83431 A1	11/01	WO		/	English (
1		1 288 199 A1	03/03	EP	 	\checkmark	abstract	
100	BJ	00/31105	06/00	WO	-	4		
190	BK	00/31103						
THER DO	CUMEI	HTS (including Auth	or, Title, Da	ite, Belevant Pages, Pla	e of Pu	blication)	
XC	BT	of Biological Ch	emistry,	Human Macrophage Met V. 270, 1995, pp. 14	568-145	75.		
4	BU	Sayda M. Elbashir et al., "Functional Anatomy of siRNAs for Mediating Efficient RNAi in <i>Drosophila melanogaster</i> Embryo Lysate," The EMBO Journal, V. 20, 2001, pp. 6877-6888.						
Ke	BV	Steven D. Shapiro et al., "Cloning and Characterization of a Unique Elastolytic Metalloproteinase Produced by Human Alveolar Macrophages," The Journal of Biological Chemistry," V. 268, 1993, pp. 23824-23829.						
KL	ВХ	Karl-Heinz Altmann et al., "Novel Chemistry," Chapter 4, Applied Antisense Oligonucleotide Technology, 1998, pp. 73-107.						
W	BY	Martin H. Holtmann et al., "Immunotherapeutic Approaches to Inflammatory Bowel Diseases," Expert Opinion on Biological Therapy, 2001, pp. 455-466.						
EXAMINE	1 /4	1100		DATE CONSIDERED		1231	_	

EXAMINER: Initial citation considered. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form Y£T (3/94)